<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A plasma protein is required as a cofactor for the binding of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> to <z:chebi fb="1" ids="16247">phospholipids</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>This protein has been identified as beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I, an <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> that binds to negatively charged <z:chebi fb="1" ids="16247">phospholipids</z:chebi> and is a natural inhibitor of the coagulation cascade </plain></SENT>
<SENT sid="2" pm="."><plain>It is not certain whether <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> bind to beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I alone, to beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> complex, or to a <z:chebi fb="0" ids="16247">phospholipid</z:chebi> <z:chebi fb="0" ids="53000">epitope</z:chebi> modified by beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I </plain></SENT>
<SENT sid="3" pm="."><plain>We used isolated beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I and purified IgG and IgM <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> from serum or plasma of patients with the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> to study the relation between <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I in enzyme-linked immunosorbent assays </plain></SENT>
<SENT sid="4" pm="."><plain>IgG <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> did not bind to beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I when it was used as an antigen on the assay plate </plain></SENT>
<SENT sid="5" pm="."><plain>The binding of IgG and IgM <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> to <z:chebi fb="0" ids="16247">phospholipid</z:chebi> was enhanced when beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I was added to the <z:chebi fb="0" ids="16247">phospholipid</z:chebi> antigens either before or together with the <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The degree of enhancement varied across patients </plain></SENT>
<SENT sid="7" pm="."><plain>IgM <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> required less cofactor for binding to <z:chebi fb="0" ids="16247">phospholipid</z:chebi> antigens </plain></SENT>
<SENT sid="8" pm="."><plain>These results confirm the requirement of beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I as a cofactor for the binding of autoimmune <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> to <z:chebi fb="1" ids="16247">phospholipids</z:chebi> </plain></SENT>
</text></document>